◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksA › AELIS

Aelis Farma SA (AELIS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-29

Aelis Farma SA (AELIS) operates in the Biotechnology industry and is headquartered in Bordeaux, France with about 16 employees. Its market capitalization is roughly €14 million. In the fiscal year ended 2025-12-31, AELIS reported €0M in revenue and (€6M) in net income.

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.

Interactive charts & full statements →

AELIS Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue€0M€3M€9M€4M
Operating Income (EBIT)(€6M)(€8M)(€6M)(€8M)
Net Income(€6M)(€8M)(€5M)(€14M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AELIS Free Cash Flow History

AELIS Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets€12M€20M€26M€39M
Total Liabilities€8M€10M€13M€19M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AELIS viewer.

Other Companies in Biotechnology

← AEJLAll “A” companiesAELV →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.